Tumor organoids: bridging models and medicine

Cancer remains a major global public health burden, and therapeutic progress has been constrained by preclinical models that inadequately recapitulate three-dimensional (3D) tumor architecture, cellular heterogeneity, and the tumor microenvironment (TME). Tumor organoids effectively address these limitations. Established directly from patient tissues or generated via malignant transformation of normal organoids, they faithfully preserve key histopathological and molecular features of parental tumors in vitro. This review synthesizes recent advances facilitating the translation of organoid technology toward clinical application, including standardized patient-derived biobanks, microfluidic organ-on-a-chip (OOC) platforms, co-culture strategies integrating immune and stromal components, and multi-omics approaches linking molecular features with functional drug responses. As experimentally tractable patient-derived models, tumor organoids enable investigation of tumor initiation, clonal evolution, metastasis, and therapeutic resistance. They also support individualized drug-sensitivity profiling, high-throughput screening, and evaluation of complex modalities such as immunotherapy, radiotherapy, and antibody-drug conjugates. Despite these advances, limitations in standardization, biological fidelity, turnaround time, and regulatory frameworks impede widespread clinical adoption. Future efforts must prioritize context-specific model design, clinically interpretable metrics, and rigorous prospective validation to transition organoids from research tools into implementable platforms for functional precision oncology.